
Short-Term Prophylaxis With Sebetralstat, an Investigational Oral On-Demand Treatment for Hereditary Angioedema, in KONFIDENT-S

Jonathan A. Bernstein,¹ Marc A. Riedl,² William R. Lumry,³ Paul K. Audhya,⁴ Michael D. Smith,^{4*} Christopher M. Yea⁴ ¹University of Cincinnati College of Medicine and Bernstein Clinical Research Center, LLC, Cincinnati, OH, US; ⁴KalVista Pharmaceuticals, Salisbury, UK, and Cambridge, MA, US *Presenting author

- surgical, or dental procedures in patients with HAE^{1,2}
- has been associated with significantly fewer HAE attacks^{3–5}
- preparation, venous access, injection site–associated pain, and discomfort^{6,7}
- sebetralstat for up to 2 years in patients aged \geq 12 years with HAE type I or II¹⁰
- be evaluated

- HAE will be enrolled in KONFIDENT-S (**Figure 1**)



- apart (**Figure 2**)
- All uses of sebetralstat as STP treatment will be recorded in each patient's diary, which records the type of procedure as well as any attack characteristics if an attack occurs

Acknowledgments

The trial was supported by KalVista Pharmaceuticals Ltd. The authors acknowledge the scientific contributions of Matthew Iverson MPH; Edward Duckworth; Erik Hansen, PhD; and Sally L. Hampton of KalVista Pharmaceuticals to this study. Medical writing assistance was provided under the direction of the authors by Katherine Stevens-Favorite, PhD, of Cadent, a Syneos Health group company, and was supported by KalVista Pharmaceuticals, Inc.

D)
J٨	
Bi	C
Ge	e
Bi	C
Re	9
W	F
CS	2
an	1

For the q4h and q2h dosing schedules, arithmetic mean plasma concentration of sebetralstat remained >1000 ng/mL between the first and third doses

prior to the second dose and 749.8 ng/mL at 28 hours and thereafter

Disclosures


AB has received speaker or consultancy fees from or served as a principal investigator for KalVista, Celldex, Pharvaris, iomarin, Amgen, Allakos, CSL Behring, Shire, Pharming, BioCryst, AstraZeneca, Sanofi-Regeneron, Novartis, and enentech. MAR has received research grants from BioCryst, CSL Behring, Ionis, KalVista, Pharvaris; consulted for ioCryst, Biomarin, CSL Behring, Cycle Pharma, Fresenius Kabi, Ionis, KalVista, Pfizer, Pharming, Pharvaris, RegenexBio, egeneron, Shire/Takeda, and Spark; and provided speaker presentations for CSL Behring, Grifols, Pharming, and Shire. RL is a member of advisory boards for BioCryst, CSL Behring, and Takeda; has received research grants from BioCryst, SL Behring, Fresenius Kabi, Pharming, and Takeda; payments for lectures from CSL Behring, Pharming, and Takeda; nd is an advisory board member of the US Hereditary Angioedema Association. PKA, MDS, and CMY are employees of KalVista Pharmaceuticals.


References

- 1. Maurer M, et al. *Allergy*. 2022;77:1961-1990. 2. Busse PJ, et al. *J Allergy Clin Immunol Pract*. 2021;9(1):132-150.e3. 3. Bork K, et al. Oral Surg Oral Med Oral Pathol Oral Radiol Endod.
- 2011;112(1):58-64.
- 2013;23(1):1-6.

A 6-hour interval was chosen to allow flexibility







PKa, plasma kallikrein activity; q8h, every 8 hours; SD, standard deviation

- Berinert. Package insert. CSL Behring; 2021.
- 7. Cinryze. Package insert. Takeda Pharmaceuticals U.S.A., Inc.; 2021. 12. Iverson M, et al. Presented at: C1 Inhibitor Deficiency and Aygören-Pürsün E, et al. Lancet. 2023;401:458-469.
- 9. ClinicalTrials.gov. Accessed April 6, 2023. https://clinicaltrials.gov/ ct2/show/NCT05259917 10. Clinical Trials.gov. Accessed April 6, 2023. https://clinicaltrials.gov/ ct2/show/NCT05505916

Dose 3

8838 ng/mL

(92.8%)

7136 ng/mL

(32.8%)

15,627 ng/mL

(32.2%)

- 4. Farkas H, et al. *Allergy*. 2012;67(12):1586-1593. 5. Jurado-Palomo J, et al. *J Investig Allergol Clin Immunol*.

Angioedema Workshop, May 4–7, 2023; Budapest, Hungary. 13. Riedl MA, et al. Presented at: WSAAI 60th Annual Scientific Session, February 5–9, 2023; Kamuela, HI US (poster 39).



Please scan this QR code to view the poster after the congress presentation